Discovery of Novel Bruton’s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.3c00176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Yi-Qian Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Study of Drug Action, Stony Brook University, John S. Toll Drive, Stony Brook, New York 11794-3400, United States. Hauptthemen laut MEDLINE: B-Lymphocytes, Protein-Tyrosine Kinases, Proteolysis Targeting Chimera. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.
Abstract (Originalsprache)
Bruton's tyrosine kinase (BTK) is a target for treating B-cell malignancies and autoimmune diseases, and several BTK inhibitors are already approved for use in humans. Heterobivalent BTK protein degraders are also in development, based on the premise that proteolysis targeting chimeras (PROTACs) may provide additional therapeutic benefits. However, most BTK PROTACs are based on the BTK inhibitor ibrutinib raising concerns about their selectivity profiles, given the known off-target effects of ibrutinib. Here, we disclose the discovery and in vitro characterization of BTK PROTACs based on the selective BTK inhibitor GDC-0853 and the cereblon recruitment ligand pomalidomide. PTD10 is a highly potent BTK degrader (DC50 0.5 nM) that inhibited cell growth and induced apoptosis at lower concentrations than the two parent molecules, as well as three previously reported BTK PROTACs, and had improved selectivity compared to ibrutinib-based BTK PROTACs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Advanced Study of Drug Action, Stony Brook University, John S. Toll Drive, Stony Brook, New York 11794-3400, United States.
- Department of Chemistry, Stony Brook University, John S. Toll Drive, Stony Brook, New York 11794-3400, United States.
- Enzymlogic S.L., QUBE Technology Park, C/ Santiago Grisolía, 2, Madrid 28760, Spain.
- Department of Pathology, Stony Brook University, John S. Toll Drive, Stony Brook, New York 11794-8691, United States.
- Department of Radiology, Stony Brook University, John S. Toll Drive, Stony Brook, New York 11794-3400, United States.
ORCID-Profile: Peter J Tonge
Förderung
- NIGMS NIH HHS
- National Institute of General Medical Sciences
Zitieren
APA
Li, Y. Q., Lannigan, W. G., Davoodi, S., Daryaee, F., Corrionero, A., Alfonso, P., Rodriguez-Santamaria, J. A., Wang, N., Haley, J. D., & Tonge, P. J. (2023). Discovery of Novel Bruton’s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c00176
Vancouver
Li YQ, Lannigan WG, Davoodi S, Daryaee F, Corrionero A, Alfonso P, et al. Discovery of Novel Bruton’s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c00176
BibTeX
@article{Li2023,
author = {Li, Yi-Qian and Lannigan, William G and Davoodi, Shabnam and Daryaee, Fereidoon and Corrionero, Ana and Alfonso, Patricia and Rodriguez-Santamaria, Jose A and Wang, Nan and Haley, John D and Tonge, Peter J},
title = {Discovery of Novel Bruton’s Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.3c00176}
}
EUVIMED